Innovative research unveiled on February 5, 2026, highlights the promising role of monthly GLP-1 therapies in the management of obesity. This new data, featured on Drug Topics, demonstrates that monthly dosing can be as effective as more frequent dosages, offering a streamlined and potentially more patient-friendly alternative for obesity treatment. GLP-1, or glucagon-like peptide-1, is a hormone that plays a significant role in appetite regulation and weight loss, making it a focal point in the fight against obesity. Monthly administration could improve compliance and convenience, especially for those struggling with current treatment regimens. These findings hold the potential to revolutionize how obesity is managed, making treatments more accessible and less burdensome for patients. By enhancing our understanding of obesity management, this breakthrough could pave the way for more individualized and effective approaches to weight loss.
Drug TopicsNew data shows smarter solutions to change-of-mind returns as retailers crack down
August 3, 2026
In a bid to address the rising costs associated with change-of-mind returns, many retailers are implementing stricter policies. However, recent data suggests that a more